Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03655821
Other study ID # IMPROVE-II
Secondary ID
Status Terminated
Phase Phase 4
First received
Last updated
Start date February 1, 2019
Est. completion date May 11, 2021

Study information

Verified date May 2022
Source Radboud University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Rationale: Pemetrexed is a multi-targeted folate antagonist, which is primarily indicated for the treatment of advanced non-small cell lung cancer (NSCLC) and mesothelioma. Dosing of cytotoxic agents like pemetrexed requires balancing the dual risk of sub-therapy and toxicity. Administration of pemetrexed to patients with a creatinine clearance <45 ml/min is currently not advised. Pemetrexed is dosed based on body surface area (BSA), while renal function and dose are the sole determinants for systemic exposure. This causes 3 major issues: 1. In patients with renal dysfunction, BSA-based dosing may lead to haematological toxicity 2. Patients have to discontinue treatment due to declining renal function, and are withheld effective treatment 3. Even in patients with adequate renal function (GFR >45 ml/min) treatment may be improved by individualized dosing based on renal function, resulting in less toxicity. Also, BSA-based dosing may lead to ineffective therapy in patients with above average renal function. The investigators aim to address these problems. Objective: The overall main objective is to develop a safe and effective individualized dosing regimen for pemetrexed. Study design: IMPROVE-II is an open label, double arm, randomized study to compare renal function-based dosing of pemetrexed versus BSA-based dosing on attainment of therapeutic exposure. Study population: IMPROVE-II includes 94 patients with NSCLC or mesothelioma that are eligible for pemetrexed treatment. Intervention: patients will be randomized in a 1:1 ratio to Arm A (BSA-based dosing according drug label) or to Arm B (renal function based dosing). The renal function-based dose will be calculated to reach the target AUC. Pharmacokinetic assessment after administration will be performed after the first pemetrexed dose in both arms. Main study endpoints: The fraction (percentage) of patients with attainment of therapeutic exposure with BSA-based dosing versus renal function-based dosing. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The investigators consider the extra burden from participating in the planned studies limited. The extra interventions compared to routine care, consist of sampling extra blood. The pharmacokinetic assessments require placement of one additional intravenous catheter. To ensure minimal impact of study participation on daily life, a limited sampling strategy will be used. Patients may benefit from participating in IMPROVE I and -II, as they will be treated with a potentially safe and effective drug that is dosed individually, which prevents toxic exposure.


Recruitment information / eligibility

Status Terminated
Enrollment 81
Est. completion date May 11, 2021
Est. primary completion date May 11, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. =18 years old 2. Eligible for treatment with pemetrexed-based chemotherapy 3. Creatinine clearance >45ml/min 4. Eastern Cooperative Oncology Group (ECOG) performance score of 0-2 5. Subject is able and willing to sign the Informed Consent Form Exclusion Criteria: 1. Conditions that affect haemostasis in a way that blood drawing is complicated (to be assessed by physician) 2. Contraindications for treatment with pemetrexed in line with the summary of product characteristics (SmPC) (except for creatinine clearance <45 ml/min in IMPROVE-I) 1. Hypersensitivity to the active substance or to any of the excipients 2. Pregnancy or lactation 3. Concomitant yellow fever vaccine 3. The presence of clinically relevant pharmacokinetic interactions, according to the current SmPC

Study Design


Intervention

Drug:
Pemetrexed
Dosing is either based on BSA or renal function

Locations

Country Name City State
Netherlands Jeroen Bosch Hospital 's-Hertogenbosch
Netherlands Antoni van Leeuwenhoek Amsterdam
Netherlands Maastricht University Medical centre Maastricht
Netherlands Radboud university medical centre Nijmegen
Netherlands Erasmus University Medical Centre Rotterdam

Sponsors (2)

Lead Sponsor Collaborator
Radboud University Medical Center ZonMw: The Netherlands Organisation for Health Research and Development

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Exposure (AUC) mg*h/l 24 hours
Primary The fraction (percentage) of patients with attainment of therapeutic exposure with BSA-based dosing versus renal function-based dosing. The fraction (percentage) of patients with attainment of therapeutic exposure defined as an AUC of 164 mg*h/l ±25%, with pemetrexed dosing based on renal function versus BSA-based dosing. 3 months
Secondary Population Clearance (Cl) L/h 3 months
Secondary Population Intercompartmental Clearance (Q) L/h 3 months
Secondary Population Central Volume of Distribution (V1) L 24 hours
Secondary Population Peripheral Volume of Distribution (V2) L 3 months
Secondary Performance of different renal function algorithms to predict pemetrexed Significant change in objective function value (OFV) (<3.84 with 1 degree of freedom) 3 months
Secondary Performance of different renal function algorithms to predict pemetrexed pharmacokinetics (decrease in variability) Decrease in clearance variablity (%) 3 months
Secondary Hematologic assessment during dosing based on renal function in patients with a creatinine clearance >45ml/min versus dosing based on BSA. Complete blood count (no per liter) 5 days
Secondary The incidence of hematologic dose limiting toxicities (DLT) and adverse events, as measured with the CTCAE V4' through listing 3 months
Secondary The incidence of non-hematologic dose limiting toxicities (DLT) and adverse events, as measured with the CTCAE V4 through listing 3 months
Secondary The incidence of toxicity-related dose reductions, treatment delays and treatment discontinuation through listing 3 months
Secondary Quality of life measured with the EORTC QLQ-C30/L13 questionnaire 0-100 scale 3 months
Secondary In silico evaluation of neutropenic response Simulation of risk for neutropenic response 1 year
Secondary Neutropenia related costs Euros 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Recruiting NCT05707286 - Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Completed NCT01945021 - Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC Phase 2
Completed NCT04487457 - Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
Terminated NCT04022876 - A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection) Phase 1
Recruiting NCT05898763 - TEIPP Immunotherapy in Patients With NSCLC Phase 1/Phase 2
Recruiting NCT05532696 - Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients Phase 1/Phase 2
Completed NCT04311034 - A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT03177291 - Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC Phase 1
Terminated NCT03257722 - Pembrolizumab + Idelalisib for Lung Cancer Study Phase 1/Phase 2
Completed NCT00349089 - Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy Phase 2
Completed NCT05116891 - A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT04571632 - Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors Phase 2
Terminated NCT03599518 - DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer Phase 1
Not yet recruiting NCT06020989 - Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy Phase 2
Withdrawn NCT03982134 - PDR001 + Panobinostat for Melanoma and NSCLC Phase 1
Withdrawn NCT03574649 - QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer Phase 2
Withdrawn NCT02844140 - DE-CT in Lung Cancer Proton Therapy N/A
Completed NCT03780010 - Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC Phase 1